205 results on '"Bernabeu, E."'
Search Results
2. AB0957 PROFILE OF REAL WORLD AXIAL SPONDYLOARTHRITIS PATIENTS REFRACTORY TO ADVANCED THERAPY
3. AB1010 DRUG-INDUCED LUPUS: CLINICAL AND SEROLOGICAL FEATURES IN A TERTIARY HOSPITAL
4. AB0750 ASSOCIATION OF ANTI-CarP LEVELS WITH THE SEROLOGICAL PROFILE IN PATIENTS WITH RHEUMATOID ARTHRITIS
5. AB0928 USE OF RITUXIMAB IN SYSTEMIC SCLEROSIS PATIENTS WITH PULMONARY AND DIFFUSE CUTANEOUS INVOLVEMENT. A SERIES OF 15 CASES
6. POS0645 REAL LIFE SAFETY AND SURVIVAL OF TARGETED THERAPIES IN ARTHRITIS PATIENTS OVER AGE OF 65
7. AB1337 COVID-19 AND JAKI: ANALYSIS AFTER THREE-YEAR PANDEMIC AT A SPANISH TERTIARY CARE HOSPITAL
8. AB1587 EXPERIENCE IN REAL-WORLD CONDITIONS OF THE EFFECTIVENESS OF THE VACCINE AGAINST HERPES ZOSTER
9. AB0476 AFTER JAK INHIBITOR FAILURE, ‘SWITCHING’ OR ‘CYCLING’?
10. AB1424 CLINICAL VARIABILITY IN PATIENTS DIAGNOSED OF JUVENILE IDIOPATHIC ARTHRITIS WITH POSITIVE AND NEGATIVE ANTINUCLEAR ANTIBODIES (ANA)
11. AB1236 OSTEOPOROSIS AND FRACTURES IN PATIENTS UNDERGOING CHRONIC CORTICOSTEROID THERAPY
12. AB0426 PROFILE OF REFRACTORY RA PATIENTS FOR TARGETED THERAPIES IN REAL LIFE
13. A PARAMETRIC METHODOLOGY FOR THE ASSIGMENT OF PRESSURE VALUES VERSUS REFRACTIVE MEASUREMENT
14. PO.3.61 Renal involvement and cardiovascular risk in systemic lupus erythematosus patients
15. PO.5.116 Lupus nephritis response in terms of kidney function, urine sediment and serological activity after belimumab treatment
16. AB0534 PROSPECTIVE STUDY OF 24 MONTHS OF EVOLUTION OF A COHORT OF PATIENTS WITH RHUPUS
17. AB0327 CARDIOVASCULAR RISK ASSESSMENT IN RHEUMATOID ARTHRITIS WITH CAROTID ULTRASONOGRAPHY AND CARDIOVASCULAR RISK SCORES: A CASE CONTROL STUDY
18. AB0435 LUPUS NEPHRITIS RESPONSE IN TERMS OF KIDNEY FUNCTION, URINE SEDIMENT AND SEROLOGICAL ACTIVITY AFTER SUBCUTANEOUS BELIMUMAB TREATMENT
19. POS0544 REMOTE MONITORING TOOLS IN RA PATIENTS: FACIT-FATIGUE AND HAQ
20. AB0324 SAFETY PROFILE OF JAK INHIBITORS IN REAL WORLD FROM A SINGLE CENTER COHORT
21. AB0411 IMPACT OF GENDER IN JAK INHIBITORS PRESCRIPTION: ANALYSIS FROM A SINGLE CENTER COHORT
22. AB1168 CLINICAL AND SEROLOGICAL EVOLUTION OF RHEUMATIC PATIENTS INFECTED BY SARS-COV-2
23. POS0191 ANTIMALARIAL DRUGS AND ELECTROCARDIOGRAPHIC ALTERATIONS IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS.
24. AB1316 PREVALENCE, DIAGNOSTIC DELAY AND TREATMENT PROFILE OF PATIENTS WITH MONOGENIC AUTOINFLAMMATORY DISEASES IN AN ADULT RHEUMATOLOGY SERVICE OF A TERTIARY HOSPITAL.
25. AB0233 CARDIOVASCULAR EVENTS IN PATIENTS WITH RHEUMATOID ARTHRITIS: A TWO YEARS OBSERVATIONAL STUDY.
26. AB1024 SECONDARY PREVENTION OF VERTEBRAL FRACTURES SUSTAINED EFFICACY OVER TIME
27. AB1256 TRANSITIONAL CARE IN JUVENILE IDIOPATHIC ARTHRITIS: TIMING, PREVALENCE OF SUBTYPES AND TREATMENT PROFILE IN A SPANISH TERTIARY HOSPITAL.
28. POS0067 PULMONARY FUNCTION IN PATIENTS DIAGNOSED OF EARLY SYSTEMIC SCLEROSIS: 10 YEARS EXPERIENCE.
29. POS1365 ANNALYSIS OF PRO-INFLAMMATORY BIOMARKERS IN A POLYMYALGIA RHEUMATICA COHORT DURING THE ACUTE ONSET OF THE DISEASE
30. POS1157 CONCORDANCE BETWEEN THE QUANTIFERON-TB GOLD IN-TUBE AND TUBERCULIN TEST FOR THE DIAGNOSIS OF LATENT TUBERCULOSIS INFECTION IN PATIENTS WITH RHEUMATIC DISEASES
31. AB0502 HEALTH-RELATED QUALITY OF LIFE MEASURES IN SPONDYLOARTHROPATY PATIENTS UNDER BIOLOGICAL THERAPIES IN REAL LIFE
32. POS0167 SECONDARY PREVENTION OF VERTEBRAL FRACTURES IN REAL PRACTICE
33. AB1066 EFFICACY AND SAFETY OF APREMILAST IN BEHÇET DISEASE PATIENTS
34. AB0165 THE ROLE OF CXCL4, CXCL8 AND GDF-15 IN SYSTEMIC SCLEROSIS
35. AB1048 RHUPUS SYNDROME IN A TERTIARY HOSPITAL
36. SAT0077 CARDIOVASCULAR RISK ASSESSMENT WITH CAROTID ULTRASONOGRAPHY IN ADDITION TO THE TRADITIONAL CARDIOVASCULAR RISK FACTORS IN RHEUMATOID ARTHRITIS PATIENTS: A CASE CONTROL STUDY
37. FRI0437 CT GUIDED NEEDLE BIOPSY IN VERTEBRAL OSTEOMYELITIS: RELIABILITY ANALYSIS AND STUDY OF WHICH FACTORS COULD INFLUENCE ON THE RESULT
38. AB0597 PULMONARY FUNCTION IN PATIENTS DIAGNOSED OF EARLY SYSTEMIC SCLEROSIS: A NEW TOOL FOR SYSTEMIC SCLEROSIS CLASIFFICATION?
39. FRI0124 EFFICACY AND SAFETY OF BARICITINIB AND TOFACITINIB IN RHEUMATOID ARTHRITIS: DATA FROM REAL-WORLD
40. PJM's Pseudo-Tie Screening Criteria Based on Electrical Distance
41. Recommended Methods for Establishing Interconnection Reliability Operating Limits in North America
42. A neural network approach for chatter prediction in turning
43. Voltage Distribution Factors for Post Contingency Local Load Relief Warning
44. AB0754 Long-term follow-up of 214 primary raynaud’s phenomenon patients
45. AB1138 High levels of anti-u1rnp and anti-sm in mixed connective tissue disease patients
46. Cascading Trees & Power System Resiliency
47. PS1:8 Anti-ro false-negatives detection through anti-ro52 kda and anti-ro60 kda analysis in systemic lupus erythematous patients
48. PS7:147 Clinical experience of belimumab treatment in clinical practice of sle patients
49. PS1:22 Use of interferon alpha and interleukin-10 as clinical activity biomarkers in systemic lupus erythematous patients
50. PS2:30 Systemic lupus erythematosus patients with positives autoantibodies with remission or low activity exhibit both lower interferon alpha and interleukin-10 levels
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.